/219A.T

219A.T Stock - Heartseed, Inc.

Q: What is the analyst price target for 219A.T?

Analyst price target information is not currently available for 219A.T.

Q: What is 219A.T's market cap?

Market capitalization information is not currently available for 219A.T.

Healthcare|Medical - Pharmaceuticals|JPX

$1785.00-1.16%

$21.00 (-1.16%) • Dec 23

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $1963.50

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for 219A.T

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2022

FY2023

FY2024

FY2025

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.41

52W High$4385.00

52W Low$1343.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2025	FY2024	FY2023	FY2022
Revenue	$3.03B	$873.61M	$344.73M	$499.06M
Gross Profit	N/A	$873.61M	$344.73M	$499.06M
Gross Margin	0.0%	100.0%	100.0%	100.0%
Operating Income	$726.44M	$-1,038,802,000	$-1,459,614,000	$-1,458,590,000
Net Income	$592.50M	$-812,725,000	$-1,473,500,000	$-1,412,728,000
Net Margin	19.6%	-93.0%	-427.4%	-283.1%
EPS	$26.28	$-36.57	$-66.99	$-64.22

Company Overview

Heartseed, Inc. engages in the provision of cardiac regenerative medicine. The company was founded by Keiichi Fukuda, Takumi Akiyama, Toshiharu Furukawa and Yutaro Kasai on November 30, 2015 and is headquartered in Tokyo, Japan.

Visit Website

Earnings History & Surprises

219A.T

Beat Rate

Last 0 quarters

Avg Surprise

+0%

EPS vs Estimate

Beats / Misses

0/0

Last 12 quarters

Latest EPS

$-20.45

Q3 2025

EPS Surprise History

Q3 24

No data

Q4 24

No data

Q1 25

No data

Q3 25

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q3 2025	Jul 31, 2025	—	$-20.45	—	—
Q2 2025	Jun 12, 2025	—	—	—	—
Q1 2025	Mar 13, 2025	—	$-21.52	—	—
Q4 2024	Dec 13, 2024	—	$12.41	—	—
Q3 2024	Sep 12, 2024	—	—	—	—
Q3 2024	Jul 30, 2024	—	$-16.75	—	—

Frequently Asked Questions about 219A.T

What is 219A.T's current stock price?

Heartseed, Inc. (219A.T) is currently trading at $1785.00 per share. The stock has moved -1.16% today.

What is the analyst price target for 219A.T?

No analyst price targets are currently available for this stock.

What sector is Heartseed, Inc. in?

Heartseed, Inc. operates in the Healthcare sector, specifically within the Medical - Pharmaceuticals industry. The company is traded on the JPX exchange.

What is 219A.T's market cap?

Heartseed, Inc. has a market capitalization of $40.72 billion, making it a large-cap company.

Does 219A.T pay dividends?

No, Heartseed, Inc. does not currently pay a dividend to shareholders.